Visual fields in neuro-ophthalmology

Indian Journal of Ophthalmology

Volumn 59, Issue 2, 2011, Pages 103-109

  Kedar, Sachin ^a   Ghate, Deepta ^a   Corbett, James J ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Hemianopia; ischemic optic neuropathy; optic chiasm; optic neuritis; perimetry; visual fields

Indexed keywords

ANTICONVULSIVE AGENT; ETHAMBUTOL; TUBERCULOSTATIC AGENT; VIGABATRIN;

BRAIN PSEUDOTUMOR; CHEMICALLY INDUCED DISORDER; CONFERENCE PAPER; HUMAN; HYPOPHYSIS TUMOR; METHODOLOGY; MULTIPLE SCLEROSIS; NEUROLOGY; OPHTHALMOLOGY; OPTIC NERVE DISEASE; PERIMETRY; VISUAL DISORDER;

ANTICONVULSANTS; ANTITUBERCULAR AGENTS; ETHAMBUTOL; HUMANS; MULTIPLE SCLEROSIS; NEUROLOGY; OPHTHALMOLOGY; OPTIC NERVE DISEASES; PITUITARY NEOPLASMS; PSEUDOTUMOR CEREBRI; VIGABATRIN; VISION DISORDERS; VISUAL FIELD TESTS;

EID: 79952379836     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.77013     Document Type: Conference Paper

References (73)

1. Trobe JD, Acosta PC, Krischer JP, Trick GL. Confrontation visual field techniques in the detection of anterior visual pathway lesions. Ann Neurol 1981;10:28-34. (Pubitemid 11093255)
2. Johnson LN, Baloh FG. The accuracy of confrontation visual field test in comparison with automated perimetry. J Natl Med Assoc 1991;83:895-8.
3. Pandit RJ, Gales K, Griffiths PG. Effectiveness of testing visual fields by confrontation. Lancet 2001;358:1339-40. (Pubitemid 33016500)
4. Shahinfar S, Johnson LN, Madsen RW. Confrontation visual field loss as a function of decibel sensitivity loss on automated static perimetry. Implications on the accuracy of confrontation visual field testing. Ophthalmology 1995;102:872-7.
5. Wirtschafter JD, Hard-Boberg AL, Coffman SM. Evaluating the usefulness in neuro-ophthalmology of visual field examinations peripheral to 30 degrees. Trans Am Ophthalmol Soc 1984;82:329-57. (Pubitemid 15102509)
6. Szatmáry G, Biousse V, Newman NJ. Can Swedish interactive thresholding algorithm fast perimetry be used as an alternative to goldmann perimetry in neuro-ophthalmic practice? Arch Ophthalmol 2002;120:1162-73. (Pubitemid 35034337)
7. Stiebel-Kalish H, Lusky M, Yassur Y, Kalish Y, Shuper A, Erlich R, et al. Swedish interactive thresholding algorithm fast for following visual fields in prepubertal idiopathic intracranial hypertension. Ophthalmology 2004;111:1673-5. (Pubitemid 39179681)
8. Wall M, Neahring RK, Woodward KR. Sensitivity and specificity of frequency doubling perimetry in neuro-ophthalmic disorders: a comparison with conventional automated perimetry. Invest Ophthalmol Vis Sci 2002;43:1277-83. (Pubitemid 34258303)
9. Noval S, Contreras I, Rebolleda G, Muñoz-Negrete FJ, Ruiz de Zárate B. A comparison between Humphrey and frequency doubling perimetry for chiasmal visual field defects. Eur J Ophthalmol 2005;15:739-45. (Pubitemid 43074700)
10. Thomas D, Thomas R, Muliyil JP, George R. Role of frequency doubling perimetry in detecting neuro-ophthalmic visual field defects. Am J Ophthalmol 2001;131:734-41. (Pubitemid 32522642)
11. Huang CQ, Carolan J, Redline D, Taravati P, Woodward KR, Johnson CA, et al. Humphrey Matrix perimetry in optic nerve and chiasmal disorders: comparison with Humphrey SITA standard 24-2. Invest Ophthalmol Vis Sci 2008;49:917-23.
12. Taravati P, Woodward KR, Keltner JL, Johnson CA, Redline D, Carolan J, et al. Sensitivity and specificity of the Humphrey Matrix to detect homonymous hemianopias. Invest Ophthalmol Vis Sci 2008;49:924-8.
13. Keltner JL, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MO. Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Ocular Hypertension Treatment Study Group. Arch Ophthalmol 2000;118:1187-94.
14. Wall M, Johnson CA, Kutzko KE, Nguyen R, Brito C, Keltner JL. Long-and short-term variability of automated perimetry results in patients with optic neuritis and healthy subjects. Arch Ophthalmol 1998;116:53-61. (Pubitemid 28098894)
15. Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology 2002;59:1492-5. (Pubitemid 35387052)
16. Corbet JJ, Savino PJ, Thompson HS, Kansu T, Schatz NJ, Orr LS, et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss.. Arch Neurol 1982;39:461-74. (Pubitemid 12089644)
17. Grehn F, Knorr-Held S, Kommerell G. Glaucomatous like visual field defects in chronic papilledema. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1981;217:99-109. (Pubitemid 11061841)
18. Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 1991;114:155-80.
19. Salgarello T, Tamburrelli C, Falsini B, Giudiceandrea A, Coloto A. Optic nerve diameters and perimetric thresholds in idiopathic intracranial hypertension. Br J Ophthalmol 1996;80:509-14. (Pubitemid 26187087)
20. Wall M, George D. Visual loss in pseudotumor cerebri. Incidence and defects related to visual field strategy. Arch Neurol 1987;44:170-5. (Pubitemid 17002600)
21. Wall M, Punke SG, Stickney TL, Brito CF, Withrow KR, Kardon RH. SITA standard in optic neuropathies and hemianopias: a comparison with full threshold testing. Invest Ophthalmol Vis Sci 2001;42:528-37. (Pubitemid 32121490)
22. Keltner JL, Johnson CA, Beck RW, Cleary PA, Spurr JO. Quality control functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT). Control Clin Trials 1993;14:143-59. (Pubitemid 23102302)
23. Keltner JL, Johnson CA, Spurr JO, Beck RW. Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol 1993;111:231-4. (Pubitemid 23053574)
24. Keltner JL, Johnson CA, Spurr JO, Beck RW. Visual field profile of optic neuritis. One-year follow-up in the Optic Neuritis Treatment Trial. Arch Ophthalmol 1994;112:946-53. (Pubitemid 24228255)
25. Kupersmith MJ, Gal RL, Beck RW, Xing D, Miller N; Optic Neuritis Study Group. Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome. Neurology 2007;69:508-14. (Pubitemid 47357257)
26. Keltner JL, Johnson CA, Cello KE, Dontchev M, Gal RL, Beck RW, et al. Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years. Arch Ophthalmol 2010;128:330-7.
27. Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology 2008;115:1079-82.
28. Fang JP, Lin RH, Donahue SP. Recovery of visual field function in the optic neuritis treatment trial. Am J Ophthalmol 1999;128:566-72. (Pubitemid 29528592)
29. Keltner JL, Johnson CA, Spurr JO, Beck RW. Comparison of central and peripheral visual field properties in the optic neuritis treatment trial. Am J Ophthalmol 1999;128:543-53. (Pubitemid 29528590)
30. Kahana LM. Toxic ocular effects of ethambutol. CMAJ 1987;137:213-6. (Pubitemid 17134381)
31. Cornblath WT, Calvert PC. Best catch from NANOSNET. J Neuroophthalmol 2002;22:123-8. (Pubitemid 34693873)
32. Choi SY, Hwang JM. Optic neuropathy associated with ethambutol in Koreans. Korean J Ophthalmol 1997;11:106-10.
33. Asayama T. Two cases of bitemporal hemianopsia due to ethambutol. Jpn J Clin Ophthalmol 1969;23:1209-12.
34. Menon V, Jain D, Saxena R, Sood R. Prospective evaluation of visual function for early detection of ethambutol toxicity. Br J Ophthalmol 2009;93:1251-4.
35. Lee EJ, Kim SJ, Choung HK, Kim JH, Yu YS. Incidence and clinical features of ethambutol-induced optic neuropathy in Korea. J Neuroophthalmol 2008;28:269-77.
36. Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. Vigabatrin: 2008 update. Epilepsia 2009;50:163-73.
37. Hayreh SS, Zimmerman B. Visual field abnormalities in nonarteritic anterior ischemic optic neuropathy: their patern and prevalence at initial examination. Arch Ophthalmol 2005;123:1554-62. (Pubitemid 41626692)
38. Falavarjani KG, Sanjari MS, Modarres M, Aghamohammadi F. Clinical profile of patients with nonarteritic anterior ischemic optic neuropathy presented to a referral center from 2003 to 2008. Arch Iran Med 2009;12:472-7.
39. Feldon SE. Computerized expert system for evaluation of automated visual fields from the Ischemic Optic Neuropathy Decompression Trial: methods, baseline fields, and six-month longitudinal follow-up. Trans Am Ophthalmol Soc 2004;102:269-303. (Pubitemid 40706103)
40. Traustason OI, Feldon SE, Leemaster JE, Weiner JM. Anterior ischemic optic neuropathy: classification of field defects by Octopus automated static perimetry. Graefes Arch Clin Exp Ophthalmol 1988;226:206-12.
41. Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: natural history of visual outcome. Ophthalmology 2008;115:298-305.
42. Scherer RW, Feldon SE, Levin L, Langenberg P, Katz J, Keyl PM, et al. Visual fields at follow-up in the Ischemic Optic Neuropathy Decompression Trial: evaluation of change in patern defect and severity over time. Ophthalmology 2008;115:1809-17.
43. Hayreh SS. Posterior ischaemic optic neuropathy: clinical features, pathogenesis, and management. Eye (Lond) 2004;18:1188-206. (Pubitemid 39591802)
44. Newman NJ, Biousse V, Newman SA, Bhati MT, Hamilton SR, Farris BK, et al. Progression of visual field defects in leber hereditary optic neuropathy: experience of the LHON treatment trial. Am J Ophthalmol 2006;141:1061-7.
45. Sadun F, De Negri AM, Carelli V, Salomao SR, Berezovsky A, Andrade R, et al. Ophthalmologic findings in a large pedigree of 11778/Haplogroup J Leber hereditary optic neuropathy. Am J Ophthalmol 2004;137:271-7. (Pubitemid 38220999)
46. Carroll WM, Mastaglia FL. Leber's optic neuropathy: A clinical and visual evoked potential study of affected and asymptomatic members of a six generation family. Brain 1979;102:559-80. (Pubitemid 10224213)
47. Kjer P. Infantile optic atrophy with dominant mode of inheritance: a clinical and genetic study of19 Danish families. Acta Ophthalmol Suppl 1959;164:1-147.
48. Votruba M, Fitzke FW, Holder GE, Carter A, Bhatacharya SS, Moore AT. Clinical features in affected individuals from 21 pedigrees with dominant optic atrophy. Arch Ophthalmol 1998;116:351-8. (Pubitemid 28124402)
49. Walters JW, Gaume A, Pate L. Short wavelength-automated perimetry compared with standard achromatic perimetry in autosomal dominant optic atrophy. Br J Ophthalmol 2006;90:1267-70. (Pubitemid 44621490)
50. Fujimoto N, Saeki N, Miyauchi O, Adachi-Usami E. Criteria for early detection of temporal hemianopia in asymptomatic pituitary tumor. Eye (Lond) 2002;16:731-8. (Pubitemid 35460551)
51. Kerrison JB, Lynn MJ, Baer CA, Newman SA, Biousse V, Newman NJ. Stages of improvement in visual fields after pituitary tumor resection. Am J Ophthalmol 2000;130:813-20. (Pubitemid 32000864)
52. Gnanalingham KK, Bhattacharjee S, Pennington R, Ng J, Mendoza N. The time course of visual field recovery following transphenoidal surgery for pituitary adenomas: predictive factors for a good outcome. J Neurol Neurosurg Psychiatry 2005;76:415-9. (Pubitemid 40299136)
53. Hudson H, Rissell C, Gauderman WJ, Feldon SE. Pituitary tumor volume as a predictor of postoperative visual field recovery. Quantitative analysis using automated static perimetry and computed tomography morphometry. J Clin Neuroophthalmol 1991;11:280-3.
54. Rivoal O, Brézin AP, Feldman-Billard S, Luton JP. Goldmann perimetry in acromegaly: a survey of 307 cases from 1951 through 1996. Ophthalmology 2000;107:991-7.
55. Zhang X, Kedar S, Lynn MJ, Newman NJ, Biousse V. Homonymous hemianopias: clinical-anatomic correlations in 904 cases. Neurology 2006;66:906-10. (Pubitemid 43739768)
56. Kedar S, Zhang X, Lynn MJ, Newman NJ, Biousse V. Congruency in homonymous hemianopia. Am J Ophthalmol 2007;143:772-80. (Pubitemid 46601393)
57. Zhang X, Kedar S, Lynn MJ, Newman NJ, Biousse V. Natural history of homonymous hemianopia. Neurology 2006;66:901-5. (Pubitemid 43739767)
58. Kedar S, Zhang X, Lynn MJ, Newman NJ, Biousse V. Pediatric homonymous hemianopia. J AAPOS 2006;10:249-52. (Pubitemid 43928685)
59. Reding MJ, Potes E. Rehabilitation outcome following initial unilateral hemispheric stroke. Life table analysis approach. Stroke 1988;19:1354-8.
60. Mangione CM, Lee PP, Pits J, Gutierrez P, Berry S, Hays RD. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol 1998;116:1496-504. (Pubitemid 28520671)
61. Cole SR, Beck RW, Moke PS, Gal RL, Long DT. The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Optic Neuritis Treatment Trial. Invest Ophthalmol Vis Sci 2000;41:1017-21. (Pubitemid 30187536)
62. Noble J, Forooghian F, Sproule M, Westall C, O'Connor P. Utility of the National Eye Institute VFQ-25 questionnaire in a heterogeneous group of multiple sclerosis patients. Am J Ophthalmol 2006;142:464-8. (Pubitemid 44691760)
63. Okamoto Y, Okamoto F, Hiraoka T, Yamada S, Oshika T. Visionrelated quality of life in patients with pituitary adenoma. Am J Ophthalmol 2008;146:318-22.
64. Gall C, Lucklum J, Sabel BA, Franke GH. Vision-and health-related quality of life in patients with visual field loss after postchiasmatic lesions. Invest Ophthalmol Vis Sci 2009;50:2765-6.
65. Chen CS, Lee AW, Clarke G, Hayes A, George S, Vincent R, et al. Vision-related quality of life in patients with complete homonymous hemianopia post stroke. Top Stroke Rehabil 2009;16:445-53.
66. Gall C, Franke GH, Sabel BA. Vision-related quality of life in first stroke patients with homonymous visual field defects. Health Qual Life Outcomes 2010;8:33.
67. Papageorgiou E, Hardiess G, Schaeffel F, Wiethoelter H, Karnath HO, Mallot H, et al. Assessment of vision-related quality of life in patients with homonymous visual field defects. Graefes Arch Clin Exp Ophthalmol 2007;245:1749-58. (Pubitemid 350154008)
68. Warren M. Pilot study on activities of daily living limitations in adults with hemianopsia. Am J Occup Ther 2009;63:626-33.
69. Schuet S. The rehabilitation of hemianopic dyslexia. Nat Rev Neurol 2009;5:427-37.
70. Bowers AR, Mandel AJ, Goldstein RB, Peli E. Driving with hemianopia, I: Detection performance in a driving simulator. Invest Ophthalmol Vis Sci 2009;50:5137-47.
71. Wood JM, McGwin G Jr, Elgin J, Vaphiades MS, Braswell RA, DeCarlo DK, et al. On-road driving performance by persons with hemianopia and quadrantanopia. Invest Ophthalmol Vis Sci 2009;50:577-85.
72. Silveira S, Jolly N, Heard R, Clunas NJ, Kay L. Current licensing authority standards for peripheral visual field and safe on-road senior aged automobile driving performance. Clin Experiment Ophthalmol 2007;35:612-20. (Pubitemid 47491217)
73. International Council of Ophthalmology (ICO). Visual Standards. Vision requirements for driving safety. Available from: htp://www.icoph.org/pdf/ visionfordriving.pdf Visual field techniques [last accessed on 2010 May 2].